A First in Human Study of the First in Class Fatty Acid Synthase (FASN) Inhibitor TVB-2640. Results of Dose Escalation in Mono and Combination and Evidence of Preliminary Activity
EORTC-NCI-AACR International Conference
poster
Biomarker Analyses from Dose Escalation and Expansion Phases of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients
EORTC-NCI-AACR International Conference
FASN inhibition studies in preclinical tumor models identify biomarkers that align with in vitro and in vivo sensitivity to TVB-2640
EORTC-NCI-AACR International Conference
Translational Studies of a First-in-class FASN Inhibitor, TVB-2640, Linking Preclinical Studies to Clinical Laboratory Observations in Solid Tumor Patients
AACR Special Conference: Metabolism and Cancer
